Hicks Caitlin W, Lue Jennifer, Glebova Natalia O, Ehlert Bryan A, Black James H
Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, Johns Hopkins Hospital, Baltimore, Md.
Section of Vascular Surgery and Endovascular Therapy, Department of Surgery, University of Colorado Denver, Aurora, Colo.
J Vasc Surg. 2017 Nov;66(5):1406-1416. doi: 10.1016/j.jvs.2017.03.451. Epub 2017 Jun 22.
Aortic reconstruction for complex thoracoabdominal aortic aneurysms (TAAAs) can be challenging, especially in patients with connective tissue disorders (CTDs) in whom tissue fragility is a major concern. Branched graft reconstruction is a more complex operation compared with inclusion patch repair of the aorta but is frequently necessary in patients with CTDs or other pathologies because of anatomic reasons. We describe our institutional experience with open branched graft reconstruction of aortic aneurysms and compare outcomes for patients with CTDs vs degenerative pathologies.
We retrospectively analyzed all patients undergoing open aortic reconstruction using branched grafts at our institution between July 2006 and December 2015. Postoperative outcomes, including perioperative morbidity and mortality, midterm graft patency, and the development of new aneurysms, were compared for patients with CTD vs degenerative disease.
During the 10-year study period, 137 patients (CTD, 29; degenerative, 108) underwent aortic repair with branched graft reconstruction. CTD patients were significantly younger (39 ± 1.9 vs 68 ± 1.0 years; P < .001) and had fewer comorbidities (hypertension, chronic obstructive pulmonary disease, coronary artery disease; P < .05) but a higher prevalence of aortic dissections (55% vs 16%; P < .001) and aneurysms involving the thoracic aorta (90% vs 60%; P = .003) than patients with degenerative disease. Perioperative mortality (CTD: 10% [n = 3] vs degenerative: 6% [n = 6]; P = .40) and any complication (62% vs 55%; P = .47) were similar between groups. At a median follow-up time of 14.5 months (interquartile range: 6.5, 43.9 months), CTD patients were more likely to develop both new aortic (21%) and nonaortic (14%) aneurysms compared with the degenerative group (7% and 4% for aortic and nonaortic aneurysms, respectively; P = .02). Loss of branch graft patency occurred in 0 of 99 grafts (0%) in CTD patients and in 13 of 167 grafts (7.8%) in degenerative disease patients (P = .005). Loss of branch graft patency occurred most commonly in left renal artery bypass grafts (77%) and was clinically asymptomatic (creatinine: 1.77 ± 0.13 mg/dL currently vs 1.41 ± 0.25 preoperatively; P = .22).
CTD patients with aortic aneurysms who undergo open branched graft reconstruction have reasonable outcomes compared with patients with degenerative pathology, including better branched graft patency and a similar risk of perioperative mortality and complications. Open repair of aortic aneurysms with branched graft reconstruction can be performed safely in both populations with low perioperative mortality, but ongoing surveillance is critical for the detection of new aneurysms, especially among patients with CTD.
复杂胸腹主动脉瘤(TAAA)的主动脉重建具有挑战性,尤其是对于结缔组织病(CTD)患者,其组织脆弱性是主要问题。与主动脉包容补片修复相比,分支移植物重建是一种更复杂的手术,但由于解剖学原因,在CTD患者或其他病变患者中经常需要进行。我们描述了我们机构开放分支移植物重建主动脉瘤的经验,并比较了CTD患者与退行性病变患者的结局。
我们回顾性分析了2006年7月至2015年12月期间在我们机构接受使用分支移植物进行开放主动脉重建的所有患者。比较了CTD患者与退行性疾病患者的术后结局,包括围手术期发病率和死亡率、中期移植物通畅率以及新发动脉瘤的发生情况。
在10年的研究期间,137例患者(CTD患者29例,退行性病变患者108例)接受了分支移植物重建的主动脉修复。CTD患者明显更年轻(39±1.9岁对68±1.0岁;P<.001),合并症更少(高血压、慢性阻塞性肺疾病、冠状动脉疾病;P<.05),但与退行性疾病患者相比,主动脉夹层的患病率更高(55%对16%;P<.001),累及胸主动脉的动脉瘤患病率更高(90%对60%;P=.003)。两组间围手术期死亡率(CTD组:10%[n=3]对退行性病变组:6%[n=6];P=.40)和任何并发症发生率(62%对55%;P=.47)相似。在中位随访时间14.5个月(四分位间距:6.5,43.9个月)时,与退行性病变组相比,CTD患者新发主动脉瘤(21%)和非主动脉瘤(14%)的可能性更高(主动脉瘤和非主动脉瘤分别为7%和4%;P=.02)。CTD患者99个移植物中有0个(0%)出现分支移植物通畅丧失,退行性疾病患者167个移植物中有13个(7.8%)出现分支移植物通畅丧失(P=.005)。分支移植物通畅丧失最常发生在左肾动脉旁路移植物中(77%),且临床上无症状(肌酐:目前1.77±0.13mg/dL对术前1.41±0.25mg/dL;P=.22)。
与退行性病变患者相比,接受开放分支移植物重建的主动脉瘤CTD患者有合理的结局,包括更好的分支移植物通畅率以及相似的围手术期死亡率和并发症风险。在这两类人群中,采用分支移植物重建进行主动脉瘤开放修复均可安全进行,围手术期死亡率较低,但持续监测对于发现新发动脉瘤至关重要,尤其是在CTD患者中。